Atea Pharmaceuticals
AVIR
142 hedge funds and large institutions have $1.99B invested in Atea Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 42 increasing their positions, 31 reducing their positions, and 17 closing their positions.
235% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 17
58% more capital invested
Capital invested by funds: $1.26B → $1.99B (+$727M)
38% more funds holding
Funds holding: 103 → 142 (+39)
35% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 31
10% more call options, than puts
Call options by funds: $13M | Put options by funds: $11.8M
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2.52% less ownership
Funds ownership: 71.18% → 68.67% (-2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$45.9M |
| 2 |
BlackRock
New York
|
+$17.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.9M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.86M |
| 5 |
Goldman Sachs
New York
|
+$9.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$53.1M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$41.1M |
| 3 |
AICPI
ABG Innovation Capital Partners III
Central, Hong Kong,
Hong Kong
|
-$27.2M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$17M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$16.2M |
AVIR Hedge Fund Activity: Q3 2021 in Review
142 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q3 2021, worth a combined $1.99B — up 58% from $1.26B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new AVIR positions and 17 closed out — a net gain of 40 holders — while 42 added to existing stakes and 31 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $45.9M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $53.1M.
- 142 institutional investors held Atea Pharmaceuticals (AVIR) as of Q3 2021, up from 103 in Q2 2021.
- Funds reported $1.99B of Atea Pharmaceuticals stock for Q3 2021, up 58% quarter-over-quarter.
- 57 funds opened new Atea Pharmaceuticals positions in Q3 2021 and 17 closed out, a net change of +40 holders.
- The largest Atea Pharmaceuticals buyer in Q3 2021 was Viking Global Investors, an estimated $45.9M added.
- The largest Atea Pharmaceuticals seller in Q3 2021 was Bain Capital Life Sciences Investors, an estimated $53.1M sold.
Based on aggregated 13F filings for Q3 2021.